Q-omics provides the consensus-scored FAM85B profile across patient tissues and cancer cell-line models. FAM85B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM85B is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, FAM85B RNA expression shows 14,528 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where FAM85B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM85B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM85B survival associations across molecular data types. FAM85B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM85B RNA expression–survival associations across cancer types. High FAM85B expression shows unfavorable associations in KIRP and PAAD, but favorable associations in KIRC, UVM, HNSC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM85B RNA expression.
This table summarizes FAM85B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM85B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM85B shows lower tumor expression in KICH, BLCA, THCA, BRCA, LUSC and KIRP. The KICH box plot shows higher FAM85B RNA expression in normal versus tumor tissue (log2 FC = −0.696, t-test p < 0.001).
This table shows molecular features associated with FAM85B in patient tissues and cancer cell lines. In patient samples, FAM85B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
